OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients
| Autor: | Jean-Louis Vanherweghem, Michel Goldman, Luc De Pauw, Daniel Abramowicz, Paul Kinnaert, Gerrie Estermans, Pierre Vereerstraeten, Olivier Mat, Alain Crusiaux |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Graft Rejection Nephrology medicine.medical_specialty medicine.medical_treatment Pilot Projects chemical and pharmacologic phenomena Azathioprine Gastroenterology Graft Enhancement Immunologic Internal medicine Cyclosporin a Humans Medicine Kidney transplantation Transplantation Chemotherapy business.industry Immunosuppression medicine.disease Kidney Transplantation Surgery Concomitant business Muromonab-CD3 medicine.drug |
| Zdroj: | Transplant International. 7:258-263 |
| ISSN: | 1432-2277 0934-0874 |
| DOI: | 10.1111/j.1432-2277.1994.tb01571.x |
| Popis: | The use of OKT3 as prophylaxis in renal transplantation results in a reduced incidence of graft rejection and appears to have beneficial effects on long-term kidney graft survival. However, we and others have observed that patients still experience rejection during the period of OKT3 prophylaxis given at the regular 5 mg/day dose. Many of these patients had no circulating CD3+ cells at the time of rejection, but their OKT3 serum levels were distinctly low ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink